EMA Authorised: Neuraceq (florbetaben (18F)) — Lantheus Germany GmbH

View source ↗

Summary

EMA has authorised Neuraceq (florbetaben 18F) for radionuclide imaging related to Alzheimer disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• NEURACEQ (Florbetaben F 18)

Snippet

Status: Authorised. Therapeutic area: Radionuclide Imaging;Alzheimer Disease. MAH: Lantheus Germany GmbH. Decision date: 28/04/2026